Search
XMT-1001
go.drugbank.com/drugs/DB06069InvestigationalXMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human tumor xenografts models … In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal).
Categories: Compounds used in a research, industrial, or household settingPhosphatidyl serine
go.drugbank.com/drugs/DB00144ApprovedNutraceuticalPS has been investigated in a small number of double-blind placebo trials and has been shown to increase memory performance in the elderly. … PS has been shown to slow cognitive decline in animal models.
Zanidatamab
go.drugbank.com/drugs/DB15471ApprovedInvestigational[A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903] … Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2).
Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalIn contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals [A32676]. … It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS).
Synonyms: (1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diolHexobendine
go.drugbank.com/drugs/DB13265ApprovedIt has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany [T478]. … Hexobendine is a medication used to cause vasodilation, to treat several conditions including angina pectoris.
Categories: Vasodilators Used in Cardiac DiseasesPoractant alfa
go.drugbank.com/drugs/DB09113ApprovedInvestigationalPoractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada. … It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency.
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L51998,A264878] This novel mechanism of action is effective even in the presence of inhibitors towards factors VIII or IX, as it essentially skips the intrinsic pathway in which factors VIII and IX participate … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.
Riltozinameran
go.drugbank.com/drugs/DB17095ApprovedInvestigationalThe Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]
Sibeprenlimab
go.drugbank.com/drugs/DB18919ApprovedInvestigational[L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … [A274848, A274853, A274858] Elevated APRIL levels are often observed in inflammatory disorders, including immunoglobulin A nephropathy (IgAN).
Onion
go.drugbank.com/drugs/DB10548ApprovedOnion allergenic extract is used in allergenic testing.
Mixtures: BARICUS 50 IU/%1/%10 JEL , 50 G, NOSKAR 100 MG/50 IU/10 MG / G, JEL 120 G